8.51
+0.86(+11.24%)
Currency In USD
| Previous Close | 7.65 |
| Open | 7.77 |
| Day High | 8.64 |
| Day Low | 7.77 |
| 52-Week High | 11.78 |
| 52-Week Low | 4.06 |
| Volume | 2.93M |
| Average Volume | 1.07M |
| Market Cap | 1.35B |
| PE | -6.98 |
| EPS | -1.22 |
| Moving Average 50 Days | 7.75 |
| Moving Average 200 Days | 8.28 |
| Change | 0.86 |
If you invested $1000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, it would be worth $199.06 as of March 12, 2025 at a share price of $8.51. Whereas If you bought $1000 worth of Ocular Therapeutix, Inc. (OCUL) shares 5 years ago, it would be worth $1,983.68 as of March 12, 2025 at a share price of $8.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocular Therapeutix™ to Present at Two Investor Conferences in March
GlobeNewswire Inc.
Feb 25, 2025 12:00 PM GMT
BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor confer
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
GlobeNewswire Inc.
Feb 24, 2025 12:00 PM GMT
BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on M
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
GlobeNewswire Inc.
Feb 03, 2025 12:00 PM GMT
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, a